Articles tagged with Vaccine Development
A University of Saskatchewan research team has been awarded nearly $1 million to develop animal models and test vaccine candidates for the new coronavirus. The project aims to identify suitable animal models to replicate human disease, with a goal of developing a pan-coronavirus vaccine.
Researchers at Colorado State University have discovered how a viral protein regulates genome replication in viruses like West Nile and Zika. The study found that the protein acts as a brake during unwinding, and mutations can affect replication efficiency.
A study found that childhood vaccine responses are shaped by geography, age, and anemia status. Children with anemia showed weaker immune responses to malaria vaccines in Tanzania and Mozambique.
Researchers charted immune system development in sub-Saharan African children to improve vaccine efficacy. Their findings suggest that a child's age, location, and health status influence their immune response to vaccines.
A new study shows that a Zika vaccine doesn't have to offer perfect protection to be valuable, with potential cost savings in certain situations.
A new experimental vaccine for African swine fever has shown promising results, with both low and high doses being 100% effective against the virus when challenged 28 days post-inoculation. The vaccine was developed to combat the highly contagious and lethal ASFV-G strain, which has been devastating Eastern Europe and Southeast Asia.
The Partnership for Research on Ebola Vaccination (PREVAC) has received additional funding to evaluate three Ebola vaccine regimens for long-term safety and durability. The PREVAC-UP project will assess these factors over 5 years after vaccination, as well as the impact of co-infections like malaria and helminths on immune responses.
The International Vaccine Institute (IVI) has renewed its partnership with Sweden's Swedish International Cooperation Agency (Sida) to accelerate vaccine research and development for global health. The five-year partnership will focus on infectious diseases of global importance, including cholera, typhoid, and dengue.
A landmark study by the Global Enteric Multicenter Study (GEMS) found that even mild cases of diarrheal illness can be fatal to young children. The study, published in Lancet Global Health, suggests that more aggressive action is needed to prevent and treat all cases of diarrheal illness, regardless of severity.
The International Vaccine Institute (IVI) has received a $1.4 million grant from the Bill & Melinda Gates Foundation to develop international standards for oral cholera vaccine manufacturing. This will enable multiple manufacturers to produce low-cost vaccines, meeting global demand and ensuring uniform efficacy.
Researchers have successfully tested a new immunotherapy approach that targets brain plaque and tau protein aggregates linked to Alzheimer's disease. The treatment, developed using a combination of vaccines, shows promise for preventing dementia in humans within two years.
Researchers have developed a novel way to record patient vaccination history by storing data in a pattern of invisible dye delivered under the skin. The dye remains stable for at least five years and can be detected using a specially equipped smartphone, promising to improve vaccine administration in developing nations.
Researchers at the University of Adelaide have made significant progress in developing a novel Zika virus vaccine that prevents infection in pre-clinical models. The vaccine's effectiveness has been demonstrated in mouse models, offering a promising solution to prevent congenital effects in infants born to infected mothers.
Researchers developed a Zika vaccine that safely protects both mother and fetus from the virus. However, pregnancy weakens the immune response, requiring a higher dose of vaccination to be effective.
Researchers have developed a new biotechnology platform to produce safer 'hybrid' viruses for vaccines and diagnostics against mosquito-borne diseases. The Binjari virus, inert to humans, is used to create 'dangerous-looking' viruses like Zika and dengue that cannot grow in humans or animals.
Researchers at UMSOM are testing a combined Shigella-ETEC vaccine to offer protection against diarrheal diseases, which cause millions of deaths worldwide. The vaccine has been developed with $4.5 million funding from Emergent BioSolutions.
A new method has been developed to accelerate the development of protein therapeutics by utilizing a cell-free system for glycosylation. This approach enables researchers to quickly discover and understand glycosylation pathways, leading to faster medicine creation and potentially opening up new avenues for treating diseases.
Eastern equine encephalitis virus is a deadly mosquito-borne illness that has existed for centuries, with a particularly deadly year in the US in 2019. Current research efforts focus on developing vaccines and treatments, but challenges include limited funding and difficulties in reaching target populations.
OHSU researchers have been awarded $2.1 million to develop new adjuvants that can enhance immune responses against infectious diseases. The goal is to create a range of adjuvants that can be used with different vaccines to protect against various pathogens.
Dr. Bruce Alberts will receive the 2020 John Edward Porter Legacy Award for his commitment to scientific research and education. The award recognizes his efforts to promote science as inquiry and improve science education in primary and secondary schools.
Dr. Kathleen Neuzil's pivotal research informed global vaccine policy, saving millions worldwide. As a member of the National Academy of Medicine, she will continue to shape public health policy.
Researchers have identified promising new strategies to counteract infection and develop effective vaccines. The vaccine targets both the offending microbe and its tick carrier to prevent Lyme disease.
The study found that almost complete immune capacity in the gut had developed as early as 14 weeks, with cells from both innate and adaptive immune systems present. This discovery could lead to the development of new maternal vaccines and a better understanding of the risk of autoimmune diseases.
The US FDA has approved a new smallpox vaccine called JYNNEOS, which is non-replicating and can be used to protect against both smallpox and monkeypox diseases. The vaccine developed by Bavarian Nordic was shown to have a superior immune response compared to the existing ACAM2000 vaccine.
MIT researchers have developed a delivery system that makes RNA vaccines more powerful, triggering efficient protein production and boosting immune response. The nanoparticles also activate an immune signaling pathway, provoking T cells to attack cancer cells and infectious agents.
A new type of vaccine that can be stored at warmer temperatures has been developed for Chikungunya, a disease that causes crippling headache and joint pain. The vaccine candidate has shown exceptionally promising results in animal studies, setting the stage for a future vaccine to combat the disease.
Replacing seasonal vaccines with universal ones could avert over 17 million cases and 251,000 hospitalizations per year. States with high hospitalization costs and elderly populations would experience the greatest economic benefits.
A recent study reveals that dengue virus mutations in its E protein can render vaccines and treatments ineffective. The findings also suggest that lab-adapted strains may not accurately represent clinical strains, highlighting the need for further research.
Researchers at Penn Medicine have developed a vaccine that protects against genital herpes, with almost all animal subjects exposed to the virus showing sterilizing immunity. The vaccine stimulates three types of antibodies to block the virus from entering cells and ensure innate immune system protective functions are not turned off.
The University of Maryland School of Medicine has been awarded a $200 million contract from the National Institute of Allergy and Infectious Diseases to develop and test new influenza vaccines. The research aims to protect against emerging flu strains and improve seasonal vaccines.
A Wistar team is advancing a synthetic DNA technology called DNA-encoded monoclonal antibodies (DMAbs) to combat multidrug-resistant Pseudomonas aeruginosa. The researchers have demonstrated the effectiveness of DMAbs in controlling infection in mice, paving the way for further development and clinical testing.
Researchers are developing a vaccine to counteract opioid addiction, with the goal of helping people stop the addiction and regain control of their lives. The vaccine, consisting of one shot and two boosters, aims to develop antibodies against opioids, alleviating symptoms and potentially saving lives during overdose.
Researchers developed a DNA vaccine for Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) that completely protects against lethal infection in ferrets. The vaccine induces both neutralizing antibody response and multifunctional T cell immunity.
A new study has gained insights into the mechanism of vaccine-induced T cell immunity, shedding light on the regulation, gene expression, and metabolic pathways of T cells. The discovery of a marker, TfR1, suggests that T cell immunity depends on specific metabolites.
Researchers have achieved a major breakthrough in developing a thermally stable TB vaccine using a technique called ensilication, which protects vaccine components from heat damage. This innovation has the potential to improve the effectiveness and accessibility of vaccines globally, particularly in remote areas.
Researchers at Yale University have developed a promising combination immune therapy to dramatically reduce the recurrence of genital herpes. The prime-and-pull strategy involves a vaccine and medicated cream that work together to block the virus from spreading.
A novel RSV vaccine candidate, DS-Cav1, has shown early promise in a Phase 1 clinical trial, prompting large increases in RSV-neutralizing antibodies. The vaccine induced a sevenfold increase in neutralizing antibody levels after a single dose of 50 μg and a 12-fold surge with a dose of 150 μg.
A large-scale analysis of over 200,000 individuals found no positive correlation between vaccinations and the development of multiple sclerosis. MS patients were statistically less likely to receive vaccinations before diagnosis than comparator groups.
A new, more effective influenza vaccine is being tested in the US, aiming to improve seasonal flu shot effectiveness. The vaccine uses adjuvants to enhance protection against infection, with a technology designed by artificial intelligence.
Researchers developed a new vaccine, NOMV-FHbp, which induced higher levels of protective antibodies than licensed vaccines against five of six bacterial strains. The vaccine has the potential to extend coverage to infants and toddlers, who are at high risk of developing meningococcal disease.
Researchers developed a cancer vaccine technology using live, attenuated pathogens as vectors. The novel vaccine causes the bacteria to self-destruct once they've done their job, making it safe for human use. This innovation has potential applications in treating various cancers and infectious diseases.
Researchers developed a novel mouse model of intestinal parasite infection that mimics human disease, offering protection against Cryptosporidium infection. The model uses a naturally occurring species of mouse Cryptosporidium and demonstrates the importance of T cells and interferon-gamma in immune response.
Researchers have discovered an antibody that can bind to a highly conserved region of the virus, potentially neutralizing all GII.4 strains of norovirus. This breakthrough is a significant step forward in the development of an effective vaccine for the dreaded stomach virus.
Researchers identified factors contributing to placental transfer of antibodies, including a preference for NK-activating antibodies that activate natural killer cells. This knowledge can be used to develop more effective maternal vaccines and deliver them during pregnancy to protect newborns from serious diseases like polio.
Researchers sequenced DNA of over 2,000 Group A Streptococcus samples from 22 countries to identify common genetic targets for a global vaccine. The study reveals that current vaccine candidates may have limited coverage in low-income areas where Strep A is most prevalent.
Scientists have developed a new single vaccination approach that simultaneously protects against both influenza and pneumococcal infections, overcoming the limitations of current vaccines. The approach combines vaccines targeting different components of the virus and bacteria, inducing enhanced cross-protective immunity.
A broadly effective dengue vaccine is still a substantial challenge due to the disease's complexity. However, experts suggest that rethinking existing concepts and developing live attenuated vaccines could lead to more effective solutions.
Researchers at Princeton University developed a mouse model of hepatitis C by introducing human proteins that allow the virus entry to liver cells. The study found that small mutations in a liver cell protein significantly impact viral replication in mice and humans.
The NIH has awarded four Cooperative Research Centers to develop vaccines against syphilis, gonorrhea, and chlamydia. The centers will focus on identifying vaccine candidates that could lead to safe and effective treatments for these diseases.
Researchers have developed an orally administered hepatitis B vaccine that is both effective and safe. The new vaccine uses a technique called 3D imaging to understand how the vaccine behaves in the body, leading to improved efficacy and reduced side effects.
A new study suggests that vaccination could reduce the impact of white-nose syndrome in bats by providing immunity against the fungus Pseudogymnoascus destructans. Bats immunized against Pd were less likely to develop WNS or die from the disease in two initial scientific trials.
A $10.7 million NIH grant will fund the establishment of a Gonorrhea Vaccine Cooperative Research Center, with Oregon State University's Aleksandra Sikora working to develop a vaccine against gonorrhea, a sexually transmitted disease that causes significant harm if untreated or improperly treated.
Researchers developed a novel recombinant vaccine called NIPRAB that shows strong immunization against Nipah virus in animal models. The live vaccine is safe in mice, eliciting a strong antibodies response and reacting to similar viruses like Hendra and Rabies.
InDevR to showcase VaxArray technology at the BIO International Convention, leveraging NIH SBIR/STTR funding. The company has a proven track record of translating scientific ideas into commercial products.
A potent and safe vaccine protects against MERS, a viral infection with a 35% mortality rate in 27 countries. The new vaccine platform targets specific cells without causing lung damage, offering a promising strategy for enhancing vaccine safety and potency.
Researchers at UTMB are developing rapid-acting vaccines and broad-spectrum treatments for Ebola and Marburg, two highly-lethal hemorrhagic fever viruses considered Tier 1 pathogens. The $35M NIH grant will support the creation of new vaccines and treatments to address high mortality rates ranging from 50-90%.
Experts discuss ongoing research on improving seasonal influenza vaccines and developing a universal vaccine for long-term protection against multiple seasonal and pandemic influenza viruses. Recent scientific advances have provided unprecedented momentum toward this goal.
Pediatric health researchers offer new insights for RSV vaccine development, highlighting the importance of type 1 interferons in infants' immune response. The study suggests strategies to enhance type 1 interferon responses and improve existing vaccines, offering hope for prevention of severe RSV disease in infants.
A global team of scientists has mapped a newborn's life development in unprecedented detail, revealing thousands of changes over the first week. This breakthrough study could transform our understanding of health and disease in babies, and inform the development of optimized protective measures, including vaccines.
Researchers have pioneered a technique to analyze tiny amounts of newborn blood, providing the most detailed accounting to date. The study establishes a common developmental pathway for the first week of a newborn's life, offering insights into newborn health and the impact of vaccines.